Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
82 hedge funds and large institutions have $790M invested in Avidity Biosciences in 2020 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 23 increasing their positions, 15 reducing their positions, and 14 closing their positions.
107% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 14
53% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 15
22% more funds holding
Funds holding: 67 → 82 (+15)
10.5% more ownership
Funds ownership: 72% → 82.5% (+11%)
5% more capital invested
Capital invested by funds: $755M → $790M (+$34.8M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
+$45.8M |
| 2 |
BlackRock
New York
|
+$21.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$12.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.8M |
| 5 |
TG
TCW Group
Los Angeles,
California
|
+$5.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$11M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.03M |
| 3 |
Janus Henderson Group
London,
|
-$5.08M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.2M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$2.22M |
RNAM Hedge Fund Activity: Q4 2020 in Review
82 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q4 2020, worth a combined $790M — up 4.6% from $755M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new RNAM positions and 14 closed out — a net gain of 15 holders — while 23 added to existing stakes and 15 trimmed.
The largest buyer was Alethea Capital Management, opening a new position worth an estimated $45.8M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $11M sold.
- 82 institutional investors held Avidity Biosciences (RNAM) as of Q4 2020, up from 67 in Q3 2020.
- Funds reported $790M of Avidity Biosciences stock for Q4 2020, up 4.6% quarter-over-quarter.
- 29 funds opened new Avidity Biosciences positions in Q4 2020 and 14 closed out, a net change of +15 holders.
- The largest Avidity Biosciences buyer in Q4 2020 was Alethea Capital Management, an estimated $45.8M added.
- The largest Avidity Biosciences seller in Q4 2020 was PFM Health Sciences, an estimated $11M sold.
Based on aggregated 13F filings for Q4 2020.